IPP Bureau
Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network
By IPP Bureau - October 09, 2024
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Aster implements India’s first IOeRT for cancer care
By IPP Bureau - October 09, 2024
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
By IPP Bureau - October 09, 2024
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
By IPP Bureau - October 08, 2024
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Davaindia accelerates expansion with 1,165 operational stores
By IPP Bureau - October 08, 2024
Strategic focus on COCO-model with a nationwide reach of 501 stores
AstraZeneca, CSPC Pharmaceutical agree for a pre-clinical novel lipid-lowering therapy
By IPP Bureau - October 08, 2024
CSPC will receive an upfront payment of $100 million from AstraZeneca
Lupin and Scope sign agreement for commercialization of Optase in Mexico
By IPP Bureau - October 08, 2024
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
Lupin acquires nine brands of Medical Nutritional Institute in South Africa
By IPP Bureau - October 06, 2024
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Calquence granted priority review in US for patients with untreated mantle cell lymphoma
By IPP Bureau - October 06, 2024
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories
By IPP Bureau - October 06, 2024
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark
By IPP Bureau - October 06, 2024
he company will focus on production of any pharmaceutical and biotechnological products
AIIMS, New organises conference on ‘Advancing Oral Health in India’
By IPP Bureau - October 06, 2024
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Briefs: Aurobindo Pharma and Lupin
By IPP Bureau - October 06, 2024
USFDA completes PAI of Lupin’s biotech facility in Pune
Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
By IPP Bureau - October 05, 2024
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure signs agreement with Gilead for manufacture and supply of Lenacapavir
By IPP Bureau - October 04, 2024
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
